What Quest Diagnostics's Quarter ended Sep 30, 2026 10-Q says: 5 signals
Quest Diagnostics filed its latest 10-Q with the SEC on Oct 23, 2026. It discusses AI investment, debt refinancing and digital transformation.
Public (DGX)Hospitals and Health Care10,000+ employeesquestdiagnostics.comLinkedIn
Get Quest Diagnostics' live signals in Claude or ChatGPT, or by API
What changed at Quest Diagnostics this week? Use Autobound signals for questdiagnostics.com.- Filed
- Oct 23, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 17
Source: Autobound Signal API · 71 signals tracked for Quest Diagnostics · updated
10-Q · latest 10
What Quest Diagnostics's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 5 signals
Quest Diagnostics advances multi-year Project Nova to modernize Order-to-Cash business processes
SG&A expense growth in Q3 2026 was driven in part by spending on Project Nova, a multi-year project to modernize Order-to-Cash processes.
Order-to-Cash
Quest Diagnostics and Corewell Health completed their transaction in January 2026 to form a new Michigan entity owned 51% by Quest and 49% by Corewell Health, operating until a new laboratory opens in 2027.
51%
equity ownership of the newly formed entity
Quest Diagnostics completed $500 million offering of 5.00% senior notes due June 2036
In May 2026, Quest Diagnostics completed a senior notes offering consisting of $500 million aggregate principal amount of 5.00% senior notes due June 2036.
$500M
aggregate principal amount of 5.00% senior notes offering due June 2036
5%
interest rate on 2036 senior notes
Fresenius Medical Care and Corewell Health partnerships drive 9.5% DIS volume increase
Relationships with Corewell Health and increased laboratory testing at dialysis clinics owned by Fresenius Medical Care in the United States contributed 9.5% of DIS volume growth.
9.5%
volume increase attributable to Corewell Health and Fresenius Medical Care testing
Quest Diagnostics deploys AI and automation across value chain targeting 3% annual savings
Under the Invigorate program, Quest Diagnostics is deploying artificial intelligence and automation across its entire value chain to improve productivity and quality.
3%
annual cost savings and productivity improvements target
automationartificial intelligence
- SEC EDGAR
10-Q
Filed · 6 signals
SVP Commercial Officer, General Counsel & Director adopt 10b5-1 stock selling plans in Q2 2026
SVP Chief Commercial Officer Mark Delaney, SVP General Counsel Mike Prevoznik, and Director Gary Pfeiffer all adopted new Rule 10b5-1 stock selling plans in April and May 2026.
Quest plans $550M in 2026 capital expenditures for IT, automation, and facilities
The company has allocated $550 million for 2026 capex, with a focus on modernizing IT infrastructure, implementing laboratory automation, and upgrading facilities.
$550M
Estimated 2026 capital expenditures
laboratory automationinformation technology
Billing and collection efficiency declines as Days Sales Outstanding (DSO) increases to 50 days
Days Sales Outstanding (DSO) increased from 47 to 50 days year-over-year, indicating a worsening of billing and collection efficiency.
Quest increases spending on business acquisitions and capex by $47M in H1 2026.
The company increased its net cash used in investing activities by $47 million year-over-year, explicitly citing higher spending on business acquisitions and capital expenditures.
$47M
Year-over-year increase in cash used for investing activities (capex & acquisitions) in H1 2026.
Company actively refinances debt, issuing new 2036 Senior Notes and repaying $500M in Q2 2026
Quest Diagnostics is actively managing its capital structure, having issued new 5.000% Senior Notes due 2036 while repaying $500 million of its 3.45% Senior Notes at maturity.
$500M
Repayment of 3.45% Senior Notes due June 1, 2026
The Bank of New York Mellon
Earlier 10-Q filings
- 10-QFiled · 6 signalsSEC EDGAR
Showing 10 of 17 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Quest Diagnostics earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Launching multi-year, $300M+ 'Project Nova' digital transformation with Epic.Quest is undertaking a massive 5-7 year order-to-cash transformation, deploying Epic's Beaker (LIS), MyChart, and Care Everywhere. This signals significant, long-term IT budget for modernizing systems and improving customer experience, creating opportunities for implementation partners and ancillary tech vendors. | |
| Secured $1B annual revenue joint venture with Corewell Health.Quest is establishing a massive lab services joint venture in Michigan, its largest 'Co-Lab' implementation to date. Scaling operations across Corewell's 21 hospital labs will require significant investment in supply chain, lab analytics, and operational support systems. | |
| Facing $100M revenue headwind from PAMA reimbursement cuts next year.Leadership is bracing for a potential $100 million negative impact from PAMA reimbursement cuts next year. This significant cost pressure makes the company highly receptive to solutions that can offset the loss through cost savings, process optimization, and improved efficiency. | |
| Targeting 3% annual cost savings via 'Invigorate' program using AI & automation.The ongoing 'Invigorate' program aims for 3% annual productivity gains by deploying automation and AI to digitize processes. This creates a clear opening for vendors offering solutions that improve operational efficiency, quality, and productivity with a demonstrable ROI. | |
| Facing rising employee healthcare costs, creating a significant margin headwind.The CFO explicitly identified higher-than-expected employee medical expenses as a 'fairly significant headwind' on margins, costing 40-50 basis points. This quantified pain point makes the company receptive to solutions from benefits consultants, wellness platforms, and healthcare cost containment vendors. | |
| Delivered robust revenue growth of 13.1%, with 6.8% organic growth.The company's strong top-line performance, driven by broad-based demand and acquisitions, significantly outpaces market norms. This financial strength and accelerating growth indicate a healthy company with available budget for new projects and investments. |
Signal API · MCP
Track Quest Diagnostics with the Signal API
One POST /v1/companies/enrich call with questdiagnostics.com returns Quest Diagnostics 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"questdiagnostics.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Quest Diagnostics 10-Q
When did Quest Diagnostics file its latest 10-Q?
What did Quest Diagnostics disclose in its latest 10-Q?
What did Quest Diagnostics say on its recent earnings calls?
Where can I read Quest Diagnostics's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .